Cargando…

ER stress: an emerging regulator in GVHD development

Allogeneic hematopoietic cell transplantation (allo-HCT) is a promising therapeutic option for hematologic malignancies. However, the clinical benefits of allo-HCT are limited by the development of complications including graft-versus-host disease (GVHD). Conditioning regimens, such as chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Hee-Jin, Yu, Xue-Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511645/
https://www.ncbi.nlm.nih.gov/pubmed/37744326
http://dx.doi.org/10.3389/fimmu.2023.1212215
_version_ 1785108189338927104
author Choi, Hee-Jin
Yu, Xue-Zhong
author_facet Choi, Hee-Jin
Yu, Xue-Zhong
author_sort Choi, Hee-Jin
collection PubMed
description Allogeneic hematopoietic cell transplantation (allo-HCT) is a promising therapeutic option for hematologic malignancies. However, the clinical benefits of allo-HCT are limited by the development of complications including graft-versus-host disease (GVHD). Conditioning regimens, such as chemotherapy and irradiation, which are administered to the patients prior to allo-HCT, can disrupt the endoplasmic reticulum (ER) homeostasis, and induce ER stress in the recipient’s cells. The conditioning regimen activates antigen-presenting cells (APCs), which, in turn, activate donor cells, leading to ER stress in the transplanted cells. The unfolded protein response (UPR) is an evolutionarily conserved signaling pathway that manages ER stress in response to cellular stress. UPR has been identified as a significant regulatory player that influences the function of various immune cells, including T cells, B cells, macrophages, and dendritic cells (DCs), in various disease progressions. Therefore, targeting the UPR pathway has garnered significant attention as a promising approach for the treatment of numerous diseases, such as cancer, neurodegeneration, diabetes, and inflammatory diseases. In this review, we summarize the current literature regarding the contribution of ER stress response to the development of GVHD in both hematopoietic and non-hematopoietic cells. Additionally, we explore the potential therapeutic implications of targeting UPR to enhance the effectiveness of allo-HCT for patients with hematopoietic malignancies.
format Online
Article
Text
id pubmed-10511645
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105116452023-09-22 ER stress: an emerging regulator in GVHD development Choi, Hee-Jin Yu, Xue-Zhong Front Immunol Immunology Allogeneic hematopoietic cell transplantation (allo-HCT) is a promising therapeutic option for hematologic malignancies. However, the clinical benefits of allo-HCT are limited by the development of complications including graft-versus-host disease (GVHD). Conditioning regimens, such as chemotherapy and irradiation, which are administered to the patients prior to allo-HCT, can disrupt the endoplasmic reticulum (ER) homeostasis, and induce ER stress in the recipient’s cells. The conditioning regimen activates antigen-presenting cells (APCs), which, in turn, activate donor cells, leading to ER stress in the transplanted cells. The unfolded protein response (UPR) is an evolutionarily conserved signaling pathway that manages ER stress in response to cellular stress. UPR has been identified as a significant regulatory player that influences the function of various immune cells, including T cells, B cells, macrophages, and dendritic cells (DCs), in various disease progressions. Therefore, targeting the UPR pathway has garnered significant attention as a promising approach for the treatment of numerous diseases, such as cancer, neurodegeneration, diabetes, and inflammatory diseases. In this review, we summarize the current literature regarding the contribution of ER stress response to the development of GVHD in both hematopoietic and non-hematopoietic cells. Additionally, we explore the potential therapeutic implications of targeting UPR to enhance the effectiveness of allo-HCT for patients with hematopoietic malignancies. Frontiers Media S.A. 2023-09-06 /pmc/articles/PMC10511645/ /pubmed/37744326 http://dx.doi.org/10.3389/fimmu.2023.1212215 Text en Copyright © 2023 Choi and Yu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Choi, Hee-Jin
Yu, Xue-Zhong
ER stress: an emerging regulator in GVHD development
title ER stress: an emerging regulator in GVHD development
title_full ER stress: an emerging regulator in GVHD development
title_fullStr ER stress: an emerging regulator in GVHD development
title_full_unstemmed ER stress: an emerging regulator in GVHD development
title_short ER stress: an emerging regulator in GVHD development
title_sort er stress: an emerging regulator in gvhd development
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511645/
https://www.ncbi.nlm.nih.gov/pubmed/37744326
http://dx.doi.org/10.3389/fimmu.2023.1212215
work_keys_str_mv AT choiheejin erstressanemergingregulatoringvhddevelopment
AT yuxuezhong erstressanemergingregulatoringvhddevelopment